Percheron Therapeutics Ltd
AWY0
Company Profile
Business description
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.
Contact
35 Collins Street
Level 30, Collins Place
MelbourneVIC3000
AUST: +61 398278999
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
8
Stocks News & Analysis
stocks
Undervalued ASX share with plan to mitigate tariff risk
Shares have dropped 20% in the previous year due to concerns about tariffs.
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,300.70 | 21.30 | -0.23% |
| CAC 40 | 8,239.18 | 13.55 | 0.16% |
| DAX 40 | 24,308.78 | 68.89 | 0.28% |
| Dow JONES (US) | 47,544.59 | 337.47 | 0.71% |
| FTSE 100 | 9,653.82 | 8.20 | 0.09% |
| HKSE | 26,444.38 | 10.68 | 0.04% |
| NASDAQ | 23,637.46 | 432.59 | 1.86% |
| Nikkei 225 | 50,219.62 | 292.70 | -0.58% |
| NZX 50 Index | 13,402.66 | 11.07 | 0.08% |
| S&P 500 | 6,875.16 | 83.47 | 1.23% |
| S&P/ASX 200 | 9,017.40 | 11.40 | -0.13% |
| SSE Composite Index | 4,005.44 | 8.50 | 0.21% |